The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people eligible for vaccination with the shot.

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in high-risk adults ages 18 to 59 years,

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals to safeguard infants from birth.

Americans as young as 18 with a chronic condition can now receive an RSV vaccine after Pfizer snagged expanded FDA approval this week. The shot, Abrysvo, is

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at increased risk. It is the first RSV vaccine indicated for adults younger than 50,

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to determine how much advantage will be gained from the nod as the Centers for Disease Control (CDC) will have to sign off on Abvrysvo's use in the wider age group.

The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age. Tuesday’s label expansion covers younger adults who are deemed at higher risk of RSV-related lower respiratory tract disease.

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.